SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Boehringer Ingelheim Pharmaceuticals, Inc. Release: Sustained Viral Response from Phase 2 Studies of BI 201335, Including Difficult-to-Treat HCV Patient Types